• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Epidemiol Health . Evaluation of clinical severity according to primary infection variants in patients with suspected SARS-CoV-2 reinfection

tetano

Editor, Senior Moderator
Epidemiol Health


. 2022 Dec 21;e2023007.
doi: 10.4178/epih.e2023007. Online ahead of print.
Evaluation of clinical severity according to primary infection variants in patients with suspected SARS-CoV-2 reinfection


Myung-Jae Hwang[SUP] 1 [/SUP], Insob Hwang[SUP] 1 [/SUP], Chungmin Park[SUP] 1 [/SUP], Hanul Park[SUP] 1 [/SUP], Taejong Son[SUP] 1 [/SUP], Jong-Hun Kim[SUP] 2 [/SUP]



Affiliations

Abstract

Objectives: We aimed to evaluate the severity of suspected severe acute respiratory syndrome coronavirus 2 reinfection according to the concern of variants in the Republic of Korea.
Methods: The database of COVID-19 cases reported through the integrated system in an epidemiological investigation, by the Korea Disease Control and Prevention Agency, from January 20, 2020 to May 7, 2022, was combined with the Health Insurance Review and Assessment Service system. The severity odds ratio (SOR) at secondary infection episodes compared with primary infection was estimated using a generalized linear model with binomial distribution.
Results: In all patients, the SOR of reinfection was 0.89 (95% confidence interval [CI]: 0.82-0.95), and the severity was relieved compared with their first infection episode. Patients in the vaccinated group within 91 days, the SOR was more declined than 91 days after vaccination as 0.85 (95% CI: 0.74-0.98). However, despite the vaccination, in patients with primary and secondary infections caused by Omicron, the severity was less relieved than in primarily infected episodes with other variants.
Conclusion: We could make efforts to relieve the severity of the vulnerable populations that are likely to lead to death by recommending booster vaccinations in case of a resurgence.

Keywords: COVID-19; Omicron; Reinfection; Severity; Vaccination.
 
Back
Top Bottom